Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company is planning on trading its stock on the NASDAQ under the ticker symbol “ARMO.” Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo’s backers include Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.
REDWOOD CITY, Calif., Dec. 29, 2017 /PRNewswire/ — ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. ARMO BioSciences, Inc. has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol “ARMO.”
Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the proposed offering. Robert W. Baird & Co. Incorporated is acting as co-manager.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext. 6132 or by email at Syndicate@Leerink.com; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at 800-414-3627, or by email at firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.